Browsing by Author "Djurdjevic, Katarina (59413080800)"
Now showing 1 - 1 of 1
- Results Per Page
 - Sort Options
 
- Some of the metrics are blocked by yourconsent settings
Publication Myotonic dystrophy type 1 in the COVID-19 era(2023) ;Ilic Zivojinovic, Jelena (57205711393) ;Djurdjevic, Katarina (59413080800) ;Bozovic, Ivo (57194468421) ;Meola, Giovanni (7005543642) ;Peric, Marina (55243680800) ;Azanjac Arsic, Ana (57943980700) ;Basta, Ivana (8274374200) ;Rakocevic-Stojanovic, Vidosava (6603893359)Peric, Stojan (35750481700)Introduction: Myotonic dystrophy type 1 (DM1) is the most prevalent muscular dystrophy in adults. People with DM1 might represent a high-risk population for respiratory infections, including COVID-19. Our aim was to evaluate the characteristics of COVID-19 infection and vaccination rate in DM1 patients. Methods: This cross-sectional cohort study included 89 patients from the Serbian registry for myotonic dystrophies. Mean age at testing was 48.4 ± 10.4 years with 41 (46.1%) male patients. Mean duration of the disease was 24.0 ± 10.3 years. Results: COVID-19 infection was reported by 36 (40.4%) DM1 patients. Around 14% of patients had a more severe form of COVID-19 requiring hospitalization. The severity of COVID-19 was in accordance with the duration of DM1. A severe form of COVID-19 was reported in 20.8% of patients who were not vaccinated against SARS-CoV-2 and in none of the vaccinated ones. The majority of 89 tested patients (66.3%) were vaccinated against SARS-CoV-2. About half of them (54.2%) received three doses and 35.6% two doses of vaccine. Mild adverse events after vaccination were recorded in 20.3% of patients. Conclusions: The percentage of DM1 patients who suffered from COVID-19 was like in general population, but with more severe forms in DM1, especially in patients with longer DM1 duration. The study indicated an overall favorable safety profile of COVID-19 vaccines among individuals with DM1 and its ability to protect them from severe COVID-19. © 2023, The Author(s). 
